GlassScriptPhysician profile
Sara M Westfall
NPI 1831631837
$4,938.89
in general payments reported to CMS, 2019-2025
29 companies · $711 in 2025
The $711 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,591 · 2022: $774 · 2023: $793 · 2024: $1,070 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,369.00 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Navitor, Cardiomems |
| Novartis Pharmaceuticals Corporation | $618.16 | 2021-2025 | |
| Abiomed | $556.73 | 2021-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.59 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $250.23 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $232.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.55 | 2021-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $192.08 | 2021-2024 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $177.23 | 2021-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $167.05 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $157.01 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $141.81 | 2021-2023 | Repatha |
| Scpharmaceuticals INC. | $82.41 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $81.10 | 2021 | |
| Novo Nordisk INC | $60.33 | 2023-2025 | Wegovy, Ozempic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $52.56 | 2021 | |
| Edwards Lifesciences Corporation | $48.82 | 2022-2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $43.70 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $37.22 | 2025 | Optimizer |
| Ionis Pharmaceuticals, INC. | $24.01 | 2025 | Tryngolza |
| Cvrx, INC. | $21.78 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $21.67 | 2024 | |
| Amarin Pharma, INC. | $21.03 | 2022 | |
| Chiesi USA, INC. | $17.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.14 | 2022 | |
| United Therapeutics Corporation | $16.06 | 2021 | |
| Ucb, INC. | $14.77 | 2024 | Briviact |
| Kowa Pharmaceuticals America, INC. | $14.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Westfall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.